Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2020

01-03-2020 | Metastasis

Mouse models of high-risk neuroblastoma

Authors: Alvin Kamili, Caroline Atkinson, Toby N. Trahair, Jamie I. Fletcher

Published in: Cancer and Metastasis Reviews | Issue 1/2020

Login to get access

Abstract

Informative and realistic mouse models of high-risk neuroblastoma are central to understanding mechanisms of tumour initiation, progression, and metastasis. They also play vital roles in validating tumour drivers and drug targets, as platforms for assessment of new therapies and in the generation of drug sensitivity data that can inform treatment decisions for individual patients. This review will describe genetically engineered mouse models of specific subsets of high-risk neuroblastoma, the development of patient-derived xenograft models that more broadly represent the diversity and heterogeneity of the disease, and models of primary and metastatic disease. We discuss the research applications, advantages, and limitations of each model type, the importance of model repositories and data standards for supporting reproducible, high-quality research, and potential future directions for neuroblastoma mouse models.
Literature
1.
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016). Neuroblastoma. Nature Reviews Disease Primers, 2, 16078.CrossRefPubMed
2.
Marshall, G. M., Carter, D. R., Cheung, B. B., Liu, T., Mateos, M. K., Meyerowitz, J. G., & Weiss, W. A. (2014). The prenatal origins of cancer. Nature Reviews Cancer, 14(4), 277–289.CrossRefPubMedPubMedCentral
3.
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., Kim, J., Lawrence, M. S., Lichenstein, L., McKenna, A., Pedamallu, C. S., Ramos, A. H., Shefler, E., Sivachenko, A., Sougnez, C., Stewart, C., Ally, A., Birol, I., Chiu, R., Corbett, R. D., Hirst, M., Jackman, S. D., Kamoh, B., Khodabakshi, A. H., Krzywinski, M., Lo, A., Moore, R. A., Mungall, K. L., Qian, J., Tam, A., Thiessen, N., Zhao, Y., Cole, K. A., Diamond, M., Diskin, S. J., Mosse, Y. P., Wood, A. C., Ji, L., Sposto, R., Badgett, T., London, W. B., Moyer, Y., Gastier-Foster, J. M., Smith, M. A., Guidry Auvil, J. M., Gerhard, D. S., Hogarty, M. D., Jones, S. J., Lander, E. S., Gabriel, S. B., Getz, G., Seeger, R. C., Khan, J., Marra, M. A., Meyerson, M., & Maris, J. M. (2013). The genetic landscape of high-risk neuroblastoma. Nature Genetics, 45(3), 279–284.CrossRefPubMedPubMedCentral
4.
Grobner, S. N., Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., et al. (2018). The landscape of genomic alterations across childhood cancers. Nature, 555(7696), 321–327.CrossRefPubMed
5.
Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., Huether, R., Gonzalez-Pena, V., Wilkinson, M. R., Hermida, L. C., Davis, S., Sioson, E., Pounds, S., Cao, X., Ries, R. E., Wang, Z., Chen, X., Dong, L., Diskin, S. J., Smith, M. A., Guidry Auvil, J. M., Meltzer, P. S., Lau, C. C., Perlman, E. J., Maris, J. M., Meshinchi, S., Hunger, S. P., Gerhard, D. S., & Zhang, J. (2018). Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature, 555(7696), 371–376.CrossRefPubMedPubMedCentral
6.
Weiss, W., Aldape, K., Mohapatra, G., Feuerstein, B., & Bishop, J. (1997). Targeted expression of MYCN causes neuroblastoma in transgenic mice. The EMBO Journal, 16, 2985–2995.CrossRefPubMedPubMedCentral
7.
Heukamp, L. C., Thor, T., Schramm, A., De Preter, K., Kumps, C., De Wilde, B., et al. (2012). Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science Translational Medicine, 4(141), 141ra191.CrossRef
8.
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., Ahmad, Z., Barker, K., Moreau, L., Webber, H., Wang, W., Liu, Q., Perez-Atayde, A., Rodig, S., Cheung, N. K., Raynaud, F., Hallberg, B., Robinson, S. P., Gray, N. S., Pearson, A. D., Eccles, S. A., Chesler, L., & George, R. E. (2012). The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell, 22(1), 117–130.CrossRefPubMedPubMedCentral
9.
Ueda, T., Nakata, Y., Yamasaki, N., Oda, H., Sentani, K., Kanai, A., Onishi, N., Ikeda, K., Sera, Y., Honda, Z. I., Tanaka, K., Sata, M., Ogawa, S., Yasui, W., Saya, H., Takita, J., & Honda, H. (2016). ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN. Oncogene, 35(34), 4447–4458.CrossRefPubMed
10.
Molenaar, J. J., Domingo-Fernandez, R., Ebus, M. E., Lindner, S., Koster, J., Drabek, K., et al. (2012). LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genetics, 44(11), 1199–1206.CrossRefPubMed
11.
Hansford, L. M., Thomas, W. D., Keating, J. M., Burkhart, C. A., Peaston, A. E., Norris, M. D., Haber, M., Armati, P. J., Weiss, W. A., & Marshall, G. M. (2004). Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proceedings of the National Academy of Sciences of the United States of America, 101(34), 12664–12669.CrossRefPubMedPubMedCentral
12.
Alam, G., Cui, H., Shi, H., Yang, L., Ding, J., Mao, L., Maltese, W. A., & Ding, H. F. (2009). MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. The American Journal of Pathology, 175(2), 856–866.CrossRefPubMedPubMedCentral
13.
Beckwith, J. B., & Perrin, E. V. (1963). Is situ neuroblastomas: a contribution to the natural history of neural crest tumors. The American Journal of Pathology, 43, 1089–1104.PubMedPubMedCentral
14.
Rasmuson, A., Segerstrom, L., Nethander, M., Finnman, J., Elfman, L. H., Javanmardi, N., et al. (2012). Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS One, 7(12), e51297.CrossRefPubMedPubMedCentral
15.
Weiss, W. A., Godfrey, T., Francisco, C., & Bishop, J. M. (2000). Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Research, 60(9), 2483–2487.PubMed
16.
Althoff, K., Beckers, A., Bell, E., Nortmeyer, M., Thor, T., Sprussel, A., et al. (2015). A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene, 34(26), 3357–3368.CrossRefPubMed
17.
Hackett, C. S., Hodgson, J. G., Law, M. E., Fridlyand, J., Osoegawa, K., de Jong, P. J., Nowak, N. J., Pinkel, D., Albertson, D. G., Jain, A., Jenkins, R., Gray, J. W., & Weiss, W. A. (2003). Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Research, 63(17), 5266–5273.PubMed
18.
Chesler, L., Goldenberg, D. D., Seales, I. T., Satchi-Fainaro, R., Grimmer, M., Collins, R., Struett, C., Nguyen, K. N., Kim, G., Tihan, T., Bao, Y., Brekken, R. A., Bergers, G., Folkman, J., & Weiss, W. A. (2007). Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Research, 67(19), 9435–9442.CrossRefPubMedPubMedCentral
19.
Teitz, T., Stanke, J. J., Federico, S., Bradley, C. L., Brennan, R., Zhang, J., Johnson, M. D., Sedlacik, J., Inoue, M., Zhang, Z. M., Frase, S., Rehg, J. E., Hillenbrand, C. M., Finkelstein, D., Calabrese, C., Dyer, M. A., & Lahti, J. M. (2011). Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One, 6(4), e19133.CrossRefPubMedPubMedCentral
20.
Jamin, Y., Tucker, E. R., Poon, E., Popov, S., Vaughan, L., Boult, J. K., Webber, H., Hallsworth, A., Baker, L. C., Jones, C., Koh, D. M., Pearson, A. D., Chesler, L., & Robinson, S. P. (2013). Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. Radiology, 266(1), 130–140.CrossRefPubMed
21.
Quarta, C., Cantelli, E., Nanni, C., Ambrosini, V., D'Ambrosio, D., Di Leo, K., et al. (2013). Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice. Molecular Imaging and Biology, 15(2), 194–202.CrossRefPubMedPubMedCentral
22.
Accorsi, R., Morowitz, M. J., Charron, M., & Maris, J. M. (2003). Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma. Pediatric Radiology, 33(10), 688–692.CrossRefPubMed
23.
Chesler, L., Goldenberg, D. D., Collins, R., Grimmer, M., Kim, G. E., Tihan, T., Nguyen, K., Yakovenko, S., Matthay, K. K., & Weiss, W. A. (2008). Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia, 10(11), 1268–1274.CrossRefPubMedPubMedCentral
24.
Janoueix-Lerosey, I., Lequin, D., Brugieres, L., Ribeiro, A., de Pontual, L., Combaret, V., et al. (2008). Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature, 455(7215), 967–970.CrossRefPubMed
25.
Mosse, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., et al. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 455(7215), 930–935.CrossRefPubMedPubMedCentral
26.
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P., Hogarty, M. D., London, W. B., Radhakrishnan, R., Lemmon, M. A., & Mossé, Y. P. (2014). ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell, 26(5), 682–694.CrossRefPubMedPubMedCentral
27.
De Wilde, B., Beckers, A., Lindner, S., Kristina, A., De Preter, K., Depuydt, P., et al. (2018). The mutational landscape of MYCN, Lin28b and ALK(F1174L) driven murine neuroblastoma mimics human disease. Oncotarget, 9(9), 8334–8349.CrossRefPubMed
28.
29.
Buechner, J., Tomte, E., Haug, B. H., Henriksen, J. R., Lokke, C., Flaegstad, T., et al. (2011). Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. British Journal of Cancer, 105(2), 296–303.CrossRefPubMedPubMedCentral
30.
Diskin, S. J., Capasso, M., Schnepp, R. W., Cole, K. A., Attiyeh, E. F., Hou, C., Diamond, M., Carpenter, E. L., Winter, C., Lee, H., Jagannathan, J., Latorre, V., Iolascon, A., Hakonarson, H., Devoto, M., & Maris, J. M. (2012). Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nature Genetics, 44(10), 1126–1130.CrossRefPubMedPubMedCentral
31.
Yogev, O., Barker, K., Sikka, A., Almeida, G. S., Hallsworth, A., Smith, L. M., Jamin, Y., Ruddle, R., Koers, A., Webber, H. T., Raynaud, F. I., Popov, S., Jones, C., Petrie, K., Robinson, S. P., Keun, H. C., & Chesler, L. (2016). p53 loss in MYC-driven neuroblastoma leads to metabolic adaptations supporting radioresistance. Cancer Research, 76(10), 3025–3035.CrossRefPubMed
32.
Chmielecki, J., Bailey, M., He, J., Elvin, J., Vergilio, J. A., Ramkissoon, S., Suh, J., Frampton, G. M., Sun, J. X., Morley, S., Spritz, D., Ali, S., Gay, L., Erlich, R. L., Ross, J. S., Buxhaku, J., Davies, H., Faso, V., Germain, A., Glanville, B., Miller, V. A., Stephens, P. J., Janeway, K. A., Maris, J. M., Meshinchi, S., Pugh, T. J., Shern, J. F., & Lipson, D. (2017). Genomic profiling of a large set of diverse pediatric cancers identifies known and novel mutations across tumor spectra. Cancer Research, 77(2), 509–519.CrossRefPubMed
33.
Carr-Wilkinson, J., O'Toole, K., Wood, K. M., Challen, C. C., Baker, A. G., Board, J. R., Evans, L., Cole, M., Cheung, N. K., Boos, J., Köhler, G., Leuschner, I., Pearson, A. D., Lunec, J., & Tweddle, D. A. (2010). High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed Neuroblastoma. Clinical Cancer Research, 16(4), 1108–1118.CrossRefPubMedPubMedCentral
34.
Padovan-Merhar, O. M., Raman, P., Ostrovnaya, I., Kalletla, K., Rubnitz, K. R., Sanford, E. M., Ali, S. M., Miller, V. A., Mossé, Y. P., Granger, M. P., Weiss, B., Maris, J. M., & Modak, S. (2016). Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLoS Genetics, 12(12), e1006501.CrossRefPubMedPubMedCentral
35.
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., et al. (2015). Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 47(8), 864–871.CrossRefPubMedPubMedCentral
36.
Nakamura, T., Iwamura, Y., Kaneko, M., Nakagawa, K., Kawai, K., Mitamura, K., Futagawa, T., & Hayashi, H. (1991). Deletions and rearrangements of the retinoblastoma gene in hepatocellular carcinoma, insulinoma and some neurogenic tumors as found in a study of 121 tumors. Japanese Journal of Clinical Oncology, 21(5), 325–329.PubMed
37.
Chayka, O., Corvetta, D., Dews, M., Caccamo, A. E., Piotrowska, I., Santilli, G., Gibson, S., Sebire, N. J., Himoudi, N., Hogarty, M. D., Anderson, J., Bettuzzi, S., Thomas-Tikhonenko, A., & Sala, A. (2009). Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. Journal of the National Cancer Institute, 101(9), 663–677.CrossRefPubMedPubMedCentral
38.
Teitz, T., Inoue, M., Valentine, M. B., Zhu, K., Rehg, J. E., Zhao, W., Finkelstein, D., Wang, Y. D., Johnson, M. D., Calabrese, C., Rubinstein, M., Hakem, R., Weiss, W. A., & Lahti, J. M. (2013). Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Research, 73(13), 4086–4097.CrossRefPubMedPubMedCentral
39.
Grau, E., Martinez, F., Orellana, C., Canete, A., Yanez, Y., Oltra, S., et al. (2011). Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Molecular Carcinogenesis, 50(3), 153–162.CrossRefPubMed
40.
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Medicine, 6(5), 529–535.CrossRefPubMed
41.
Stupack, D. G., Teitz, T., Potter, M. D., Mikolon, D., Houghton, P. J., Kidd, V. J., Lahti, J. M., & Cheresh, D. A. (2006). Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature, 439(7072), 95–99.CrossRefPubMed
42.
Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., de Wilde, B., Djos, A., Ora, I., Hedborg, F., Träger, C., Holmqvist, B. M., Abrahamsson, J., Peuchmaur, M., Michon, J., Janoueix-Lerosey, I., Kogner, P., Delattre, O., & Martinsson, T. (2014). Emergence of new ALK mutations at relapse of neuroblastoma. Journal of Clinical Oncology, 32(25), 2727–2734.CrossRefPubMed
43.
Suenaga, Y., Islam, S. M., Alagu, J., Kaneko, Y., Kato, M., Tanaka, Y., Kawana, H., Hossain, S., Matsumoto, D., Yamamoto, M., Shoji, W., Itami, M., Shibata, T., Nakamura, Y., Ohira, M., Haraguchi, S., Takatori, A., & Nakagawara, A. (2014). NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3beta resulting in the stabilization of MYCN in human neuroblastomas. PLoS Genetics, 10(1), e1003996.CrossRefPubMedPubMedCentral
44.
Chen, Z., Lin, Y., Barbieri, E., Burlingame, S., Hicks, J., Ludwig, A., & Shohet, J. M. (2009). Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia, 11(8), 753–762.CrossRefPubMedPubMedCentral
45.
Kishida, S., Mu, P., Miyakawa, S., Fujiwara, M., Abe, T., Sakamoto, K., Onishi, A., Nakamura, Y., & Kadomatsu, K. (2013). Midkine promotes neuroblastoma through Notch2 signaling. Cancer Research, 73(4), 1318–1327.CrossRefPubMed
46.
Ikematsu, S., Nakagawara, A., Nakamura, Y., Ohira, M., Shinjo, M., Kishida, S., & Kadomatsu, K. (2008). Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Science, 99(10), 2070–2074.CrossRefPubMed
47.
Dorstyn, L., Puccini, J., Nikolic, A., Shalini, S., Wilson, C. H., Norris, M. D., et al. (2014). An unexpected role for caspase-2 in neuroblastoma. Cell Death & Disease, 5, e1383.CrossRef
48.
Burkhart, C. A., Watt, F., Murray, J., Pajic, M., Prokvolit, A., Xue, C., Flemming, C., Smith, J., Purmal, A., Isachenko, N., Komarov, P. G., Gurova, K. V., Sartorelli, A. C., Marshall, G. M., Norris, M. D., Gudkov, A. V., & Haber, M. (2009). Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Research, 69(16), 6573–6580.CrossRefPubMedPubMedCentral
49.
Henderson, M. J., Haber, M., Porro, A., Munoz, M. A., Iraci, N., Xue, C., Murray, J., Flemming, C. L., Smith, J., Fletcher, J. I., Gherardi, S., Kwek, C. K., Russell, A. J., Valli, E., London, W. B., Buxton, A. B., Ashton, L. J., Sartorelli, A. C., Cohn, S. L., Schwab, M., Marshall, G. M., Perini, G., & Norris, M. D. (2011). ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. Journal of the National Cancer Institute, 103(16), 1236–1251.CrossRefPubMedPubMedCentral
50.
Haber, M., Smith, J., Bordow, S. B., Flemming, C., Cohn, S. L., London, W. B., Marshall, G. M., & Norris, M. D. (2006). Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. Journal of Clinical Oncology, 24(10), 1546–1553.CrossRefPubMed
51.
Murray, J., Valli, E., Yu, D. M. T., Truong, A. M., Gifford, A. J., Eden, G. L., Gamble, L. D., Hanssen, K. M., Flemming, C. L., Tan, A., Tivnan, A., Allan, S., Saletta, F., Cheung, L., Ruhle, M., Schuetz, J. D., Henderson, M. J., Byrne, J. A., Norris, M. D., Haber, M., & Fletcher, J. I. (2017). Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo. European Journal of Cancer, 83, 132–141.CrossRefPubMedPubMedCentral
52.
Norris, M. D., Smith, J., Tanabe, K., Tobin, P., Flemming, C., Scheffer, G. L., Wielinga, P., Cohn, S. L., London, W. B., Marshall, G. M., Allen, J. D., & Haber, M. (2005). Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Molecular Cancer Therapeutics, 4(4), 547–553.CrossRefPubMed
53.
Hogarty, M. D., Norris, M. D., Davis, K., Liu, X., Evageliou, N. F., Hayes, C. S., Pawel, B., Guo, R., Zhao, H., Sekyere, E., Keating, J., Thomas, W., Cheng, N. C., Murray, J., Smith, J., Sutton, R., Venn, N., London, W. B., Buxton, A., Gilmour, S. K., Marshall, G. M., & Haber, M. (2008). ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Research, 68(23), 9735–9745.CrossRefPubMedPubMedCentral
54.
Carter, D. R., Murray, J., Cheung, B. B., Gamble, L., Koach, J., Tsang, J., et al. (2015). Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblasstoma. Science Translational Medicine, 7(312), 312ra176.CrossRefPubMedPubMedCentral
55.
Evageliou, N. F., Haber, M., Vu, A., Laetsch, T. W., Murray, J., Gamble, L. D., Cheng, N. C., Liu, K., Reese, M., Corrigan, K. A., Ziegler, D. S., Webber, H., Hayes, C. S., Pawel, B., Marshall, G. M., Zhao, H., Gilmour, S. K., Norris, M. D., & Hogarty, M. D. (2016). Polyamine antagonist therapies inhibit neuroblastoma initiation and progression. Clinical Cancer Research, 22(17), 4391–4404.CrossRefPubMed
56.
Gamble, L. D., Purgato, S., Murray, J., Xiao, L., Yu, D. M. T., Hanssen, K. M., et al. (2019). Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Science Translational Medicine, 11(477).
57.
Yogev, O., Almeida, G. S., Barker, K. T., George, S. L., Kwok, C., Campbell, J., Zarowiecki, M., Kleftogiannis, D., Smith, L. M., Hallsworth, A., Berry, P., Möcklinghoff, T., Webber, H. T., Danielson, L. S., Buttery, B., Calton, E. A., da Costa, B. M., Poon, E., Jamin, Y., Lise, S., Veal, G. J., Sebire, N., Robinson, S. P., Anderson, J., & Chesler, L. (2019). In vivo modeling of chemoresistant neuroblastoma provides new insights into chemorefractory disease and metastasis. Cancer Research, 79(20), 5382–5393.CrossRefPubMed
58.
Liu, T., Tee, A. E., Porro, A., Smith, S. A., Dwarte, T., Liu, P. Y., Iraci, N., Sekyere, E., Haber, M., Norris, M. D., Diolaiti, D., Della Valle, G., Perini, G., & Marshall, G. M. (2007). Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 104(47), 18682–18687.CrossRefPubMedPubMedCentral
59.
Waldeck, K., Cullinane, C., Ardley, K., Shortt, J., Martin, B., Tothill, R. W., Li, J., Johnstone, R. W., McArthur, G., Hicks, R. J., & Wood, P. J. (2016). Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. International Journal of Cancer, 139(1), 194–204.CrossRefPubMed
60.
Faisal, A., Vaughan, L., Bavetsias, V., Sun, C., Atrash, B., Avery, S., Jamin, Y., Robinson, S. P., Workman, P., Blagg, J., Raynaud, F. I., Eccles, S. A., Chesler, L., & Linardopoulos, S. (2011). The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Molecular Cancer Therapeutics, 10(11), 2115–2123.CrossRefPubMedPubMedCentral
61.
Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H. E., Rycak, L., Jamin, Y., Thway, K., Robinson, S. P., Roels, F., Witt, O., Fischer, M., Chesler, L., & Eilers, M. (2013). Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell, 24(1), 75–89.CrossRefPubMedPubMedCentral
62.
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., Garnett, M. J., McDermott, U., Benes, C. H., Kung, A. L., Weiss, W. A., Bradner, J. E., & Stegmaier, K. (2013). Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discovery, 3(3), 308–323.CrossRefPubMedPubMedCentral
63.
Dolman, M. E., Poon, E., Ebus, M. E., den Hartog, I. J., van Noesel, C. J., Jamin, Y., et al. (2015). Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma. Clinical Cancer Research, 21(22), 5100–5109.CrossRefPubMedPubMedCentral
64.
Koach, J., Holien, J. K., Massudi, H., Carter, D. R., Ciampa, O. C., Herath, M., Lim, T., Seneviratne, J. A., Milazzo, G., Murray, J. E., McCarroll, J., Liu, B., Mayoh, C., Keenan, B., Stevenson, B. W., Gorman, M. A., Bell, J. L., Doughty, L., Hüttelmaier, S., Oberthuer, A., Fischer, M., Gifford, A. J., Liu, T., Zhang, X., Zhu, S., Gustafson, W. C., Haber, M., Norris, M. D., Fletcher, J. I., Perini, G., Parker, M. W., Cheung, B. B., & Marshall, G. M. (2019). Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface. Cancer Research, 79(21), 5652–5667.CrossRefPubMed
65.
Chesler, L., & Weiss, W. A. (2011). Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Seminars in Cancer Biology, 21(4), 245–255.CrossRefPubMedPubMedCentral
66.
Kiyonari, S., & Kadomatsu, K. (2015). Neuroblastoma models for insights into tumorigenesis and new therapies. Expert Opinion on Drug Discovery, 10(1), 53–62.CrossRefPubMed
67.
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012). The secret ally: immunostimulation by anticancer drugs. Nature Reviews. Drug Discovery, 11(3), 215–233.CrossRefPubMed
68.
Kroesen, M., Nierkens, S., Ansems, M., Wassink, M., Orentas, R. J., Boon, L., den Brok, M., Hoogerbrugge, P. M., & Adema, G. J. (2014). A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. International Journal of Cancer, 134(6), 1335–1345.CrossRefPubMed
69.
Kroesen, M., Bull, C., Gielen, P. R., Brok, I. C., Armandari, I., Wassink, M., et al. (2016). Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma. Oncoimmunology, 5(6), e1164919.CrossRefPubMedPubMedCentral
70.
Mao, Y., Eissler, N., Blanc, K. L., Johnsen, J. I., Kogner, P., & Kiessling, R. (2016). Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clinical Cancer Research, 22(15), 3849–3859.CrossRefPubMed
71.
Hidalgo, M., Amant, F., Biankin, A. V., Budinska, E., Byrne, A. T., Caldas, C., et al. (2014). Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discovery, 4(9), 998–1013.CrossRefPubMedPubMedCentral
72.
Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., et al. (2011). A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular Cancer Therapeutics, 10(8), 1311–1316.CrossRefPubMedPubMedCentral
73.
Blattmann, C., Thiemann, M., Stenzinger, A., Roth, E. K., Dittmar, A., Witt, H., et al. (2015). Establishment of a patient-derived orthotopic osteosarcoma mouse model. Journal of Translational Medicine, 13, 136.CrossRefPubMedPubMedCentral
74.
Kim, M. P., Evans, D. B., Wang, H., Abbruzzese, J. L., Fleming, J. B., & Gallick, G. E. (2009). Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nature Protocols, 4(11), 1670–1680.CrossRefPubMedPubMedCentral
75.
Monsma, D. J., Monks, N. R., Cherba, D. M., Dylewski, D., Eugster, E., Jahn, H., et al. (2012). Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. Journal of Translational Medicine, 10, 125.CrossRefPubMedPubMedCentral
76.
Daniel, V. C., Marchionni, L., Hierman, J. S., Rhodes, J. T., Devereux, W. L., Rudin, C. M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C. D., & Watkins, D. N. (2009). A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Research, 69(8), 3364–3373.CrossRefPubMedPubMedCentral
77.
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012). Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews. Clinical Oncology, 9(6), 338–350.CrossRefPubMedPubMedCentral
78.
Tsuchida, Y., Yokomori, K., Iwanaka, T., & Saito, S. (1984). Nude mouse xenograft study for treatment of neuroblastoma: effects of chemotherapeutic agents and surgery on tumor growth and cell kinetics. Journal of Pediatric Surgery, 19(1), 72–76.CrossRefPubMed
79.
Tsuchida, Y., Kanda, N., Shimatake, H., Kaneko, Y., & Notomi, T. (1988). Clinical significance of gene amplification studied in human neuroblastoma xenografts: relationship with tumor growth rate, chemotherapeutic sensitivities and levels of neuron-specific enolase. Experimental Cell Biology, 56(5), 277–284.PubMed
80.
George, B. A., Yanik, G., Wells, R. J., Martin, L. W., Soukup, S., Ballard, E. T., Gartside, P. S., & Lampkin, B. C. (1993). Growth patterns of human neuroblastoma xenografts and their relationship to treatment outcome. Cancer, 72(11), 3331–3339.CrossRefPubMed
81.
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., et al. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer, 84(10), 1424–1431.CrossRefPubMedPubMedCentral
82.
Zarzosa, P., Navarro, N., Giralt, I., Molist, C., Almazan-Moga, A., Vidal, I., et al. (2017). Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments. Clinical & Translational Oncology, 19(1), 44–50.CrossRef
83.
Stewart, E., Federico, S. M., Chen, X., Shelat, A. A., Bradley, C., Gordon, B., Karlstrom, A., Twarog, N. R., Clay, M. R., Bahrami, A., Freeman 3rd, B. B., Xu, B., Zhou, X., Wu, J., Honnell, V., Ocarz, M., Blankenship, K., Dapper, J., Mardis, E. R., Wilson, R. K., Downing, J., Zhang, J., Easton, J., Pappo, A., & Dyer, M. A. (2017). Orthotopic patient-derived xenografts of paediatric solid tumours. Nature, 549(7670), 96–100.CrossRefPubMedPubMedCentral
84.
Kamili, A., Gifford, A. J., Li, N., Mayoh, C., Chow, S., Failes, T. W., et al. (2020). Accelerating development of high-risk neuroblastoma patient-derived xenograft models for pre-clinical testing and personalised therapy. British Journal of Cancer. https://​doi.​org/​10.​1038/​s41416-019-0682-4.
85.
Rokita, J. L., Rathi, K. S., Cardenas, M. F., Upton, K. A., Jayaseelan, J., Cross, K. L., et al. (2019). Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design. Cell Reports, 29(6), 1675–1689.e1679.CrossRefPubMedPubMedCentral
86.
Ito, R., Katano, I., Kawai, K., Hirata, H., Ogura, T., Kamisako, T., Eto, T., & Ito, M. (2009). Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation, 87(11), 1654–1658.CrossRefPubMed
87.
Bondarenko, G., Ugolkov, A., Rohan, S., Kulesza, P., Dubrovskyi, O., Gursel, D., Mathews, J., O'Halloran, T. V., Wei, J. J., & Mazar, A. P. (2015). Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia, 17(9), 735–741.CrossRefPubMedPubMedCentral
88.
Zhang, L., Liu, Y., Wang, X., Tang, Z., Li, S., Hu, Y., et al. (2015). The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice. Scientific Reports, 5, 9447.CrossRefPubMedPubMedCentral
89.
Wetterauer, C., Vlajnic, T., Schuler, J., Gsponer, J. R., Thalmann, G. N., Cecchini, M., et al. (2015). Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. Prostate, 75(6), 585–592.CrossRefPubMed
90.
Braekeveldt, N., Wigerup, C., Gisselsson, D., Mohlin, S., Merselius, M., Beckman, S., Jonson, T., Börjesson, A., Backman, T., Tadeo, I., Berbegall, A. P., Ora, I., Navarro, S., Noguera, R., Påhlman, S., & Bexell, D. (2015). Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. International Journal of Cancer, 136(5), E252–E261.CrossRefPubMed
91.
Read, M., Liu, D., Duong, C. P., Cullinane, C., Murray, W. K., Fennell, C. M., Shortt, J., Westerman, D., Burton, P., Clemons, N. J., & Phillips, W. A. (2016). Intramuscular transplantation improves engraftment rates for esophageal patient-derived tumor xenografts. Annals of Surgical Oncology, 23(1), 305–311.CrossRefPubMed
92.
Khanna, C., Jaboin, J. J., Drakos, E., Tsokos, M., & Thiele, C. J. (2002). Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo, 16(2), 77–85.PubMed
93.
Braekeveldt, N., & Bexell, D. (2018). Patient-derived xenografts as preclinical neuroblastoma models. Cell and Tissue Research, 372(2), 233–243.CrossRefPubMed
94.
Talmadge, J. E., Singh, R. K., Fidler, I. J., & Raz, A. (2007). Murine models to evaluate novel and conventional therapeutic strategies for cancer. The American Journal of Pathology, 170(3), 793–804.CrossRefPubMedPubMedCentral
95.
Braekeveldt, N., Wigerup, C., Tadeo, I., Beckman, S., Sanden, C., Jonsson, J., et al. (2016). Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Letters, 375(2), 384–389.CrossRefPubMed
96.
Singh, Z. (2016). Applications and toxicity of graphene family nanomaterials and their composites. Nanotechnology, Science and Applications, 9, 15–28.CrossRefPubMedPubMedCentral
97.
de la Fuente, A., Alonso-Alconada, L., Costa, C., Cueva, J., Garcia-Caballero, T., Lopez-Lopez, R., et al. (2015). M-trap: exosome-based capture of tumor cells as a new technology in peritoneal metastasis. Journal of the National Cancer Institute, 107(9).
98.
Dong, Z., Imai, A., Krishnamurthy, S., Zhang, Z., Zeitlin, B. D., & Nor, J. E. (2013). Xenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot study. PLoS One, 8(12), e84236.CrossRefPubMedPubMedCentral
99.
Rubio-Viqueira, B., & Hidalgo, M. (2009). Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clinical Pharmacology and Therapeutics, 85(2), 217–221.CrossRefPubMed
100.
Stewart, E., Shelat, A., Bradley, C., Chen, X., Federico, S., Thiagarajan, S., Shirinifard, A., Bahrami, A., Pappo, A., Qu, C., Finkelstein, D., Sablauer, A., & Dyer, M. A. (2015). Development and characterization of a human orthotopic neuroblastoma xenograft. Developmental Biology, 407(2), 344–355.CrossRefPubMedPubMedCentral
101.
Fuchs, D., Christofferson, R., Stridsberg, M., Lindhagen, E., & Azarbayjani, F. (2009). Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments. Journal of Translational Medicine, 7, 16.CrossRefPubMedPubMedCentral
102.
Svensson, A., Backman, U., Jonsson, E., Larsson, R., & Christofferson, R. (2002). CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatric Research, 51(5), 607–611.CrossRefPubMed
103.
Henriksson, K. C., Almgren, M. A., Thurlow, R., Varki, N. M., & Chang, C. L. (2004). A fluorescent orthotopic mouse model for reliable measurement and genetic modulation of human neuroblastoma metastasis. Clinical & Experimental Metastasis, 21(6), 563–570.CrossRef
104.
Dickson, P. V., Hamner, B., Ng, C. Y., Hall, M. M., Zhou, J., Hargrove, P. W., McCarville, M., & Davidoff, A. M. (2007). In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. Journal of Pediatric Surgery, 42(7), 1172–1179.CrossRefPubMed
105.
Daudigeos-Dubus, E., LE, D. L., Rouffiac, V., Bawa, O., Leguerney, I., Opolon, P., et al. (2014). Establishment and characterization of new orthotopic and metastatic neuroblastoma models. In Vivo, 28(4), 425–434.PubMed
106.
Abbasi, M. R., Rifatbegovic, F., Brunner, C., Mann, G., Ziegler, A., Potschger, U., et al. (2017). Impact of disseminated neuroblastoma cells on the identification of the relapse-seeding clone. Clinical Cancer Research, 23(15), 4224–4232.CrossRefPubMedPubMedCentral
107.
DuBois, S. G., Kalika, Y., Lukens, J. N., Brodeur, G. M., Seeger, R. C., Atkinson, J. B., et al. (1999). Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. Journal of Pediatric Hematology/Oncology, 21(3), 181–189.CrossRefPubMed
108.
Kramer, K., Kushner, B., Heller, G., & Cheung, N. K. (2001). Neuroblastoma metastatic to the central nervous system. The memorial Sloan-Kettering cancer center experience and a literature review. Cancer, 91(8), 1510–1519.CrossRefPubMed
109.
Morgenstern, D. A., London, W. B., Stephens, D., Volchenboum, S. L., Simon, T., Nakagawara, A., Shimada, H., Schleiermacher, G., Matthay, K. K., Cohn, S. L., Pearson, A. D., & Irwin, M. S. (2016). Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: a study from the iInternational Neuroblastoma Risk Group database. European Journal of Cancer, 65, 1–10.CrossRefPubMed
110.
Almgren, M. A., Henriksson, K. C., Fujimoto, J., & Chang, C. L. (2004). Nucleoside diphosphate kinase A/nm23-H1 promotes metastasis of NB69-derived human neuroblastoma. Molecular Cancer Research, 2(7), 387–394.PubMed
111.
Hanna, C., Kwok, L., Finlay-Schultz, J., Sartorius, C. A., & Cittelly, D. M. (2016). Labeling of breast Cancer patient-derived Xenografts with traceable reporters for tumor growth and metastasis studies. Journal of Visualized Experiments, 117.
112.
Jackson, J. R., Kim, Y., Seeger, R. C., & Kim, E. S. (2016). A novel minimal residual disease model of neuroblastoma in mice. Journal of Pediatric Surgery, 51(6), 991–994.CrossRefPubMed
113.
Barry, W. E., Jackson, J. R., Asuelime, G. E., Wu, H. W., Sun, J., Wan, Z., Malvar, J., Sheard, M. A., Wang, L., Seeger, R. C., & Kim, E. S. (2019). Activated natural killer cells in combination with anti-GD2 antibody dinutuximab improve survival of mice after surgical resection of primary neuroblastoma. Clinical Cancer Research, 25(1), 325–333.CrossRefPubMed
114.
Bogenmann, E. (1996). A metastatic neuroblastoma model in SCID mice. International Journal of Cancer, 67(3), 379–385.CrossRefPubMed
115.
Zhang, L., Smith, K. M., Chong, A. L., Stempak, D., Yeger, H., Marrano, P., Thorner, P. S., Irwin, M. S., Kaplan, D. R., & Baruchel, S. (2009). In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia, 11(5), 426–435.CrossRefPubMedPubMedCentral
116.
Muhlethaler-Mottet, A., Liberman, J., Ascencao, K., Flahaut, M., Balmas Bourloud, K., Yan, P., et al. (2015). The CXCR4/CXCR7/CXCL12 axis is involved in a secondary but complex control of neuroblastoma metastatic cell homing. PLoS One, 10(5), e0125616.CrossRefPubMedPubMedCentral
117.
Seong, B. K., Fathers, K. E., Hallett, R., Yung, C. K., Stein, L. D., Mouaaz, S., Kee, L., Hawkins, C. E., Irwin, M. S., & Kaplan, D. R. (2017). A metastatic mouse model identifies genes that regulate neuroblastoma metastasis. Cancer Research, 77(3), 696–706.CrossRefPubMed
118.
Kuchimaru, T., Kataoka, N., Nakagawa, K., Isozaki, T., Miyabara, H., Minegishi, M., Kadonosono, T., & Kizaka-Kondoh, S. (2018). A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries. Nature Communications, 9(1), 2981.CrossRefPubMedPubMedCentral
119.
Lee, S., Qiao, J., Paul, P., O'Connor, K. L., Evers, M. B., & Chung, D. H. (2012). FAK is a critical regulator of neuroblastoma liver metastasis. Oncotarget, 3(12), 1576–1587.CrossRefPubMedPubMedCentral
120.
Qiao, J., Kang, J., Ishola, T. A., Rychahou, P. G., Evers, B. M., & Chung, D. H. (2008). Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 105(35), 12891–12896.CrossRefPubMedPubMedCentral
121.
Sohara, Y., Shimada, H., Scadeng, M., Pollack, H., Yamada, S., Ye, W., Reynolds, C. P., & DeClerck, Y. (2003). Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Research, 63(12), 3026–3031.PubMed
122.
Zhao, H., Cai, W., Li, S., Da, Z., Sun, H., Ma, L., et al. (2012). Establishment and characterization of xenograft models of human neuroblastoma bone metastasis. Child's Nervous System, 28(12), 2047–2054.CrossRefPubMed
123.
Mohlin, S., Hamidian, A., von Stedingk, K., Bridges, E., Wigerup, C., Bexell, D., & Påhlman, S. (2015). PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma. Cancer Research, 75(21), 4617–4628.CrossRefPubMed
124.
Infarinato, N. R., Park, J. H., Krytska, K., Ryles, H. T., Sano, R., Szigety, K. M., Li, Y., Zou, H. Y., Lee, N. V., Smeal, T., Lemmon, M. A., & Mossé, Y. P. (2016). The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven Neuroblastoma. Cancer Discovery, 6(1), 96–107.CrossRefPubMed
125.
Krytska, K., Ryles, H. T., Sano, R., Raman, P., Infarinato, N. R., Hansel, T. D., Makena, M. R., Song, M. M., Reynolds, C. P., & Mossé, Y. P. (2016). Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma. Clinical Cancer Research, 22(4), 948–960.CrossRefPubMed
126.
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., Carol, H., Tajbakhsh, M., Reynolds, C. P., Maris, J. M., Courtright, J., Keir, S. T., Friedman, H. S., Stopford, C., Zeidner, J., Wu, J., Liu, T., Billups, C. A., Khan, J., Ansher, S., Zhang, J., & Smith, M. A. (2007). The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood & Cancer, 49(7), 928–940.CrossRef
127.
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Koster, J., DeSouza, T. A., et al. (2016). The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell, 29(4), 574–586.CrossRefPubMedPubMedCentral
128.
Stewart, E., Federico, S., Karlstrom, A., Shelat, A., Sablauer, A., Pappo, A., & Dyer, M. A. (2016). The childhood solid tumor network: a new resource for the developmental biology and oncology research communities. Developmental Biology, 411(2), 287–293.CrossRefPubMed
129.
Murphy, B., Yin, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., Keir, S. T., Kurmasheva, R. T., Dvorchik, I., Wu, J., Billups, C. A., Boateng, N., Smith, M. A., Lock, R. B., & Houghton, P. J. (2016). Evaluation of alternative in vivo drug screening methodology: a single mouse analysis. Cancer Research, 76(19), 5798–5809.CrossRefPubMedPubMedCentral
130.
Meehan, T. F., Conte, N., Goldstein, T., Inghirami, G., Murakami, M. A., Brabetz, S., Gu, Z., Wiser, J. A., Dunn, P., Begley, D. A., Krupke, D. M., Bertotti, A., Bruna, A., Brush, M. H., Byrne, A. T., Caldas, C., Christie, A. L., Clark, D. A., Dowst, H., Dry, J. R., Doroshow, J. H., Duchamp, O., Evrard, Y. A., Ferretti, S., Frese, K. K., Goodwin, N. C., Greenawalt, D., Haendel, M. A., Hermans, E., Houghton, P. J., Jonkers, J., Kemper, K., Khor, T. O., Lewis, M. T., Lloyd, K. C. K., Mason, J., Medico, E., Neuhauser, S. B., Olson, J. M., Peeper, D. S., Rueda, O. M., Seong, J. K., Trusolino, L., Vinolo, E., Wechsler-Reya, R. J., Weinstock, D. M., Welm, A., Weroha, S. J., Amant, F., Pfister, S. M., Kool, M., Parkinson, H., Butte, A. J., & Bult, C. J. (2017). PDX-MI: minimal information for patient-derived tumor xenograft models. Cancer Research, 77(21), e62–e66.CrossRefPubMedPubMedCentral
Metadata
Title
Mouse models of high-risk neuroblastoma
Authors
Alvin Kamili
Caroline Atkinson
Toby N. Trahair
Jamie I. Fletcher
Publication date
01-03-2020
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-020-09855-0

Other articles of this Issue 1/2020

Cancer and Metastasis Reviews 1/2020 Go to the issue

ReviewPaper

Oral and dental considerations in pediatric cancers

ReviewPaper

Drug repurposing towards targeting cancer stem cells in pediatric brain tumors

ReviewPaper

Insights into the prenatal origin of childhood acute lymphoblastic leukemia

ReviewPaper

New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence

ReviewPaper

Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data

ReviewPaper

Clinical research tools in pediatric oncology: challenges and opportunities
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits